Abstract
To estimate the cost-utility of the currently approved Cyclin-Dependent Kinase 4 and 6 Inhibitors (CDK4/6i) as the first-line treatment in postmenopausal women with Hormone Receptor positive (HR+) and Human Epidermal Growth Factor Receptor-2 negative (HER2-) advanced/metastatic breast cancer, from the perspective of the Colombian health system.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
